
Aakash Desai Shared A Study Published In JTO on Datopotamab Deruxtecan In Patients With EGFR-mutated NSCLC
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on X:
“A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC – Journal of Thoracic Oncology.
Interesting analysis ahead of the U.S. FDA.
PDUFA date: July 12, 2025
Will we see another option in EGFRm NSCLC?”
Title: A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC
Journal: Journal of Thoracic Oncology
Authors: Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Luis Paz-Ares, Elvire Pons-Tostivint, Maurice Pérol, Enriqueta Felip, Shunichi Sugawara, Hidetoshi Hayashi, Byoung Chul Cho, George Blumenschein Jr., Elaine Shum, Jong-Seok Lee, Rebecca S. Heist, Robin Cornelissen, Wen-Cheng Chang, Dariusz Kowalski, Hong Zebger-Gong, Michael Chargualaf, Wen Gu, Lan Lan, Paul Howarth, Richard Joseph, Isamu Okamoto
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023